Literature DB >> 11806396

Fluorine-18 fluorodeoxyglucose positron emission tomography findings in spondylodiscitis: preliminary results.

A Schmitz1, J H Risse, F Grünwald, F Gassel, H J Biersack, O Schmitt.   

Abstract

Nuclear medicine procedures can be helpful in diagnosing spine infections. The purpose of the study was to evaluate the findings of positron emission tomography with fluorine-18 fluorodeoxyglucose (FGD-PET) in the detection of spondylodiscitis. We performed FDG-PET in 16 patients with suspected spondylodiscitis. All the patients were operated and underwent histopathological examination. The FDG-PET findings were graded and evaluated by two independent nuclear medicine physicians. Of the 16 patients, 12 had a histopathologically confirmed spondylodiscitis. In all these 12 patients, FDG-PET was true-positive. In the four patients without spondylodiscitis, FDG-PET showed three true-negative and one false-positive result. In spondylodiscitis, the mean standard uptake value (SUV) of FDG was 7.5 (SD+/-3.8). The PET scans depicted the paravertebral soft tissue involvement in cases of spondylodiscitis. Our first results showed that FDG-PET is a very sensitive imaging procedure in the detection of spondylodiscitis. Compared to other nuclear medicine procedures, PET enables a rapid imaging with acceptable radiation dose and high spatial resolution.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11806396      PMCID: PMC3611533          DOI: 10.1007/s005860100339

Source DB:  PubMed          Journal:  Eur Spine J        ISSN: 0940-6719            Impact factor:   3.134


  18 in total

1.  Pyogenic vertebral osteomyelitis in a breast cancer patient: report of a case.

Authors:  Hisamitsu Zaha; Mai Onomura; Yukiko Nishikuramori
Journal:  Surg Today       Date:  2012-03-01       Impact factor: 2.549

2.  Spondylodiscitis: Diagnosis and Treatment Options.

Authors:  Christian Herren; Norma Jung; Miguel Pishnamaz; Marianne Breuninger; Jan Siewe; Rolf Sobottke
Journal:  Dtsch Arztebl Int       Date:  2017-12-25       Impact factor: 5.594

Review 3.  Imaging-Based Approach to Extradural Infections of the Spine.

Authors:  Jason F Talbott; Vinil N Shah; Alina Uzelac; Jared Narvid; Rebecca A Dumont; Cynthia T Chin; David M Wilson
Journal:  Semin Ultrasound CT MR       Date:  2018-09-26       Impact factor: 1.875

4.  [Algorithm for treatment of deep spinal infections and spondylodiscitis with in situ instrumentation].

Authors:  C N Kraft; M Fell
Journal:  Orthopade       Date:  2012-01       Impact factor: 1.087

Review 5.  Expanding role of 18F-fluoro-D-deoxyglucose PET and PET/CT in spinal infections.

Authors:  Filip Gemmel; Paul C Rijk; James M P Collins; Thierry Parlevliet; Katrin D Stumpe; Christopher J Palestro
Journal:  Eur Spine J       Date:  2010-01-06       Impact factor: 3.134

6.  Evaluation of shoulder disorders by 2-[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography.

Authors:  Young Lae Moon; Sang Hong Lee; Sung Yong Park; Jae Cheol Yu; Venkat Gorthi
Journal:  Clin Orthop Surg       Date:  2010-08-03

7.  Current diagnosis and treatment of spondylodiscitis.

Authors:  Rolf Sobottke; Harald Seifert; Gerd Fätkenheuer; Matthias Schmidt; Axel Gossmann; Peer Eysel
Journal:  Dtsch Arztebl Int       Date:  2008-03-07       Impact factor: 5.594

8.  A special case of lower back pain in a 3-year-old girl.

Authors:  Davide Tassinari; Sara Forti; Michele Torella; Giovanni Tani
Journal:  BMJ Case Rep       Date:  2013-03-07

9.  Candida albicans osteomyelitis of the cervical spine.

Authors:  Jang-Gyu Cha; Hyun-Sook Hong; Yoon-Woo Koh; Hee-Kyung Kim; Jung-Mi Park
Journal:  Skeletal Radiol       Date:  2008-02-02       Impact factor: 2.199

10.  Fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan contributes to the diagnosis and management of brucellar spondylodiskitis.

Authors:  Savvas Ioannou; Sofia Chatziioannou; Spiros G Pneumaticos; Alexandra Zormpala; Nikolaos V Sipsas
Journal:  BMC Infect Dis       Date:  2013-02-07       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.